Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Neu monoclonal antibody refers to a class of monoclonal antibodies that target Neu, the rodent homolog of human epidermal growth factor receptor 2 (HER2/ErbB2). In preclinical research, these antibodies (most notably clone 7.16.4) are widely used to study HER2-positive breast cancer and tumor immunology in mouse models, as humanized anti-HER2 antibodies like trastuzumab do not cross-react with rodent Neu. These antibodies bind to the extracellular domain of Neu, inhibiting tumor cell proliferation and mediating anti-tumor immune responses through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and T-cell activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Neu monoclonal antibody.